The glucagon receptor mediates counter-regulatory glucose mobilization, primarily through hepatic Gs–cAMP signaling that promotes glycogenolysis and gluconeogenesis programs.
What it is
GCGR is the receptor for glucagon. It is densely relevant in liver biology and appears in multi-agonist peptide research that intentionally combines glucagon receptor activity with incretin receptor activity.
How it works
Glucagon-bound GCGR raises hepatocyte cAMP, activating PKA and transcriptional programs that increase glucose output. Extrahepatic receptor expression adds complexity in cardiovascular and other tissues discussed in specialist literature.
Pathway education should keep glucagon’s counter-regulatory role distinct from GLP-1’s incretin role even when both appear in the same research molecule.
Biological role
Glucagon receptor signaling helps defend against hypoglycemia and coordinates fasting metabolism. Research interest includes receptor antagonists and balanced multi-agonists.
Proteins involved
- Glucagon receptor (GCGR)
- Gs / cAMP / PKA
- CREB-linked gluconeogenic regulators
Research summary
Receptor pharmacology and mouse genetic models outline GCGR contributions to glucose and energy balance. Translational multi-agonist papers should be read with attention to receptor bias and safety endpoints.
Descriptions summarize published mechanistic frameworks. Findings from cell culture or animal models should not be interpreted as proven clinical effects in humans.
Research limitations
Scientific references
- Müller TD et al. Glucagon biology and therapeutic targeting reviews.
- Authier F, Desbuquois B. Glucagon receptor literature surveys.